First, the predictive performance of the previous model was evaluated with MAP Bayesian analysis using NONMEM v7.4. Methods A previously published population PK model for FVIII concentrate during surgery was validated using independent data from 87 children with severe haemophilia A with a median (range) age of 2.6 years (0.03-15.2) and body weight of 14 kg (4-57). Therefore, this study aimed to validate a previously published population PK model for FVIII concentrates administrated perioperatively. However, external validation of population PK models requires independent data sets and is, therefore, seldomly performed. To guarantee accurate performance of a population PK model in dose individualization, validation studies are of importance. Aims Population pharmacokinetic (PK) models are increasingly applied to perform individualized dosing of factor VIII (FVIII) concentrates in haemophilia A patients.
0 kommentar(er)
